| Project/Area Number |
24659634
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
KONDO Kazuya 徳島大学, ヘルスバイオサイエンス研究部, 教授 (10263815)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUBO Hitoshi 福島県立医科大学, 先端臨床研究センター, 准教授 (00325292)
NAKAGAWA Yasushi 徳島大学, 病院, 助教 (80380103)
TAKIZAWA Hiromitsu 徳島大学, 病院, 講師 (90332816)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 肺癌 / preclinical animal model / 同所性移植 / PET/CT / シスプラチン |
|---|
| Outline of Final Research Achievements |
We evaluated the utility of PET-CT and MD-CT to non-invasively and repeatedly monitor the inhibitory effect of CDDP and erlotinib on lung cancer in an orthotopic SCID mouse model.
We created transplantation mouse models using non-small cell lung cancer cell; Ma-44, A549, FT821 and PC9. Only PC9 has epidermal growth factor receptor mutation. FDG PET-CT using Ma-44 showed that tumor volume and SUV max were significantly correlated with postmortem tumor length measured in specimens (P=0.023). A549 did not effect for cisplatin Ma-44, FT821 and PC-9 had anti-cancer effect. PC9 had anti-cancer effect for erlotinib, and other 2 lines did not have it. The present study supports using FDG PET-CT in monitoring tumor progression and therapeutic response of lung cancer in an orthotopic model non invasively and repeatedly.
|
